Article
Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.
Infection - 1 Apr 2014
Caby F, Schneider L, Blanc C, Soulié C, Tindel M, Peytavin G, Agher R, Valantin M A, Tubiana R, Wirden M, Calvez V, Marcelin A G, Katlama C
Abstract excerpt
BACKGROUND AND PURPOSE: The lack of antiretroviral (ARV) backbone activity associated with raltegravir has been proposed as the main explanation for virological relapse observed in patients with undetectable viraemia who are switched from a ritonavir-boosted protease inhibitor (PI) to raltegravir. However ARV activity remains difficult to assess in this context. The aim of our study was to precisely assess the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
